Skip to main content


2023 SNO/ASCO CNS Cancer Conference

Accelerating therapeutic discovery and advancing care of patients with
primary and metastatic CNS malignancies.

August 10-12, 2023
 Hyatt Regency Embarcadero - San Francisco, California

Submit Abstracts Here

Abstract Deadline: Friday, March 17, 2023 11:59pm EDT

The 2023 SNO/ASCO CNS Cancer Conference — Accelerating therapeutic discovery and advancing care of patients with primary and metastatic CNS malignancies — will be held on August 10-12, 2023, in San Francisco, California. The goal of this annual Conference is to provide a deeper dive into the basic science of brain metastases and neuro-oncology clinical trials. Together we will make significant improvements in survival and quality of life of patients with primary and metastatic cancers of the central nervous system. 
This collaborative Conference will:
  • stimulate basic, translational, and clinical research in CNS metastases;
  • engage clinical researchers in innovative trial designs for primary and secondary CNS malignancies;
  • address the needs of patients with intracranial tumors.
These areas of great unmet need will be addressed in a dynamic and interactive framework. The structure brings together various disciplines to emphasize basic and translational research on brain metastases as well as clinical trial design and outcomes in primary and metastatic intracranial tumors. Research highlighting novel approaches, innovative ideas, and recent advances in neuro-oncology clinical trials will be presented and discussed. There will be a unique opportunity for collaboration and exchange of ideas between those dedicated to the science and care of patients with primary and secondary malignancies of the CNS. 

Unparalleled Networking Opportunities
This conference will provide a unique opportunity for establishing collegial relationships with other international professionals focused on improving outcomes for brain tumor patients. Against the backdrop of the vibrant city of San Francisco, the conference will provide an unparalleled platform to share scientific results, explore new treatment paradigms, develop new friendships and connect with new collaborators. The social highlight of the meeting will take place at the world-famous San Francisco Exploratorium, and will involve an evening fun, food, exploration, and dancing!

Learning Objectives
  • Identity and describe new CNS-penetrant systemic agents in the context of multidisciplinary care for the treatment of CNS metastases.
  • Discuss new developments in local therapeutic approaches and diagnostics in the treatment of CNS metastases.
  • Describe the role of the tumor microenvironment in CNS metastases.
  • Describe clinical trial designs incorporating recent advances such as liquid biopsy, novel prognostic biomarkers, and advanced neuroimaging for the treatment of CNS malignancies.
  • Identify challenges for the development and approval of novel therapies for CNS cancers.
Who Should Attend
Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care Professionals, Industry Professionals, Regulatory and Government Officials, and Patient Advocates.
Abstract Submission
Each year the organizers of the Conference welcome the submission of original research and clinical findings addressing CNS basic science research and clinical trials. This includes previously presented or not yet presented clinical trial abstracts (encore) and trials in progress. All submissions are peer-reviewed and accepted abstracts are presented as oral talks or in-person posters. Electronic posters will be available online at the start of the Conference.

Abstract submission categories in 2023:
  • Basic Science of Brain Metastases
  • Basic Science of Leptomeningeal Disease
  • Clinical Research Methods
  • Local and Multimodality Approaches
  • Neuroimaging
  • Supportive Care
  • Systemic Therapeutics (including targeted therapy, immunotherapy, antibody-drug conjugates, novel therapies)
  • Screening/Diagnostics/Prognostics
  • Trials in Progress
To submit an abstract, click here. 
Deadline for submissions is Friday March 17, 2023, 11:59 pm ET.
Accepted abstracts will be published and indexed in Neuro-Oncology Advances.  
Planning Committee Leadership
Adrienne Boire, Memorial Sloan Kettering Cancer Center 
Sarah Goldberg, Yale School of Medicine 
Co-Chairs Elect   
Priya Kumthekar, Northwestern Medicine 
Hussein Tawbi, University of Texas MD Anderson Cancer Center
Immediate Past Co-Chairs 
Priscilla Brastianos, Massachusetts General Hospital, Harvard Medical School 
Mustafa Khasraw, Duke University 
Planning Committee 
Stephen Bagley, University of Pennsylvania
Evanthia Galanis, Mayo Clinic Rochester
Vinai Gondi, Northwestern Medicine Cancer Center Warrenville and Proton Center  
Jona Hattangadi-Gluth, University of California, San Diego
Sara Hurvitz, University of California, Los Angeles
Emilie Le Rhun, University Hospital Zurich, Switzerland
Nancy Lin, Dana Farber Cancer Institute
Minesh Mehta, Miami Cancer Institute
Josh Neman, University of Southern California, Los Angeles
Michael Platten, University Medical Center Mannheim
Solmaz Sahebjam, National Cancer Institute, National Institutes of Health
Debra Nana Yeboa, University of Texas MD Anderson Cancer Center

Quick Links